Alzheimer’s Disease Drug Discovery and Development Consortium: High-Throughput Drug Screening for Alzheimer’s Disease Using Three-Dimensional Human Neural Culture Systems

2021, 2022

Alzheimer’s disease (AD) has become a significant public health problem, but the therapeutic options are limited. Recently, ADUHELM® (Biogen) has been conditionally approved as a new AD drug targeting pathogenic amyloid beta in the patient’s brain. However, there is still an urgent need for affordable and more effective AD drugs. Therefore, we aim to accelerate AD drug discovery using our three-dimensional Alzheimer’s in a Dish™ (ADiD) model as a drug screening platform. Using our 3D AD cellular models, we identified and validated novel AD drug candidates derived from unbiased natural products library screening and transcriptomic data analysis with AD patient brains. We also found that a group of anti-malarial drugs alters aggregation of the amyloid beta 42 isoforms, a major pathogenic molecule found in AD patient brains. Our findings are expected to accelerate AD drug discovery.

Funding to Date



Drug Discovery, Drug Screening Projects


Doo Yeon Kim, Ph.D.

Luisa Quinti, Ph.D.